“A-ha” Moments From AHA 2021: My Take on New Data in Heart Failure
  • CME

November 13-15, 2021; Virtual
At AHA 2021, some major clinical trials broke new ground with familiar agents while others validated management approaches previously informed largely by clinical experience. Here’s my take.
Lee R. Goldberg, MD, MPH, FACC
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: December 8, 2021 Expiration: December 7, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the expert insights and clinical application of important findings from recent heart failure studies presented at AHA 2021.


Supported by an educational grant from

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:


Lee R. Goldberg, MD, MPH, FACC

Professor of Medicine
Division of Cardiovascular Medicine
Department of Medicine
Section Chief, Advanced Heart Failure and Cardiac Transplant
University of Pennsylvania
Philadelphia, Pennsylvania

Lee R. Goldberg, MD, MPH, FACC, has disclosed that he has received funds for research support from Respircardia and consulting fees from Abbott, Respircardia, and Viscardia.


Susan Daniels, PhD
Scientific Director
Susan Daniels, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for cardiology and primary care physicians and other HCPs who care for patients with heart failure.


This multimedia initiative will address the most up-to-date information and analysis from the American Heart Association (AHA) Scientific Sessions 2021 to be held November 13-17 virtually. Immediately after the conference, 3 slide-based capsule summaries will be released, followed by 3 CME-certified expert-authored commentaries.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 08, 2021, through December 07, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expert commentary on updates to the 2022 AHA/ACC/HFSA heart failure guidelines, from Clinical Care Options (CCO)

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: May 10, 2022 Expired: May 9, 2023

Clinical Care Options (CCO): Expert commentary covering new data in HFpEF diagnosis and treatment from ACC 2022 Annual Scientific Sessions

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: April 26, 2022 Expired: April 25, 2023

Clinical Care Options (CCO): Expert commentary covering new data in HFrEF management from ACC 2022, including SODIUM-HF, PROMPT-HF, DIAMOND, and EMPULSE

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: April 20, 2022 Expired: April 19, 2023

From ACC 2022, exploratory analysis of renal outcomes with sacubitril/valsartan vs valsartan in HFpEF with and without diabetes in PARAGON-HF trial as reported by Clinical Care Options (CCO)

Released: April 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings